AZN

ASTRAZENECA PLC ORD SHS $0.25

TitleTime
Enhertu US orphan designation in gastric cancerFri 22/05/20 | 07:00
AstraZeneca advances response to COVID-19 outbreakThu 21/05/20 | 07:00
Lynparza approved in the US for prostate cancerWed 20/05/20 | 07:00
Bevespi Aerosphere approved in China for COPDMon 18/05/20 | 07:00
Enhertu US Breakthrough status for lung cancerMon 18/05/20 | 07:00
Brazikumab rights recovered by AstraZenecaMon 11/05/20 | 07:00
Lynparza gets broader US ovarian cancer approvalMon 11/05/20 | 07:00
Enhertu designated gastric cancer BTDMon 11/05/20 | 07:00
Farxiga approved by FDA for heart failure (HFrEF)Wed 06/05/20 | 07:00
Total Voting RightsFri 01/05/20 | 15:00
Result of AGMWed 29/04/20 | 16:00
AZN: first-quarter 2020 resultsWed 29/04/20 | 07:00
Lynparza shows overall survival in prostate cancerFri 24/04/20 | 07:00
Changes to arrangements for AGMFri 17/04/20 | 11:00
Tagrisso adjuvant trial overwhelmingly positiveTue 14/04/20 | 07:00
Koselugo (selumetinib) approved in the US for NF1Tue 14/04/20 | 07:00
AstraZeneca divestment of Movantik completedThu 02/04/20 | 07:00
Total Voting RightsWed 01/04/20 | 15:00
Director/PDMR ShareholdingTue 31/03/20 | 07:00
Imfinzi approved in US for small cell lung cancerMon 30/03/20 | 07:01
Farxiga CKD trial early stop for positive efficacyMon 30/03/20 | 07:00
Director/PDMR ShareholdingThu 26/03/20 | 07:00
Lokelma approved in Japan for hyperkalaemiaThu 26/03/20 | 07:00
Second Price Monitoring ExtnTue 24/03/20 | 16:41
Price Monitoring ExtensionTue 24/03/20 | 16:36
Price Monitoring ExtensionTue 24/03/20 | 12:02
Second Price Monitoring ExtnMon 23/03/20 | 16:40
Price Monitoring ExtensionMon 23/03/20 | 16:36
Second Price Monitoring ExtnMon 23/03/20 | 12:08
Price Monitoring ExtensionMon 23/03/20 | 12:03
Second Price Monitoring ExtnFri 20/03/20 | 10:20
Price Monitoring ExtensionFri 20/03/20 | 10:15
Director/PDMR ShareholdingFri 20/03/20 | 07:00
Lynparza granted orphan drug designation in JapanThu 19/03/20 | 07:00
Imfinzi confirmed overall survival in CASPIANTue 17/03/20 | 07:00
Price Monitoring ExtensionFri 13/03/20 | 16:35
Notice of AGMThu 12/03/20 | 11:00
Update on Phase III GY004 trial for cediranibThu 12/03/20 | 07:00
Director/PDMR ShareholdingTue 10/03/20 | 07:00
Update on Phase III DANUBE trial in bladder cancerFri 06/03/20 | 07:00
Filing of Form 20-F with SECWed 04/03/20 | 07:00
Annual Financial ReportTue 03/03/20 | 11:00
Total Voting RightsMon 02/03/20 | 15:00
Divestment of hypertension medicines completedMon 02/03/20 | 07:00
Director/PDMR ShareholdingThu 27/02/20 | 07:00
AstraZeneca divests global rights to MovantikTue 25/02/20 | 07:00
Director/PDMR ShareholdingWed 19/02/20 | 07:00
AZN: Full-year and Q4 2019 resultsFri 14/02/20 | 07:00
Total Voting RightsMon 03/02/20 | 15:00
AstraZeneca divests hypertension medicinesMon 27/01/20 | 07:00
Enhertu Phase II trial met primary endpointMon 27/01/20 | 07:00
Brilinta met primary endpoint in stroke trialMon 27/01/20 | 07:00
AstraZeneca to recover brazikumab (MEDI2070)Mon 27/01/20 | 07:00
Imfinzi, tremelimumab granted ODD in liver cancerMon 20/01/20 | 07:00
FDA grants Lynparza Priority Review for PROfoundMon 20/01/20 | 07:00
Lynparza granted FDA Priority Review for PAOLA-1Mon 13/01/20 | 07:01
Update on Epanova Phase III STRENGTH trialMon 13/01/20 | 07:00
Farxiga granted FDA heart failure Priority ReviewMon 06/01/20 | 07:01
Lokelma approved in China for hyperkalaemiaMon 06/01/20 | 07:00
Total Voting RightsThu 02/01/20 | 15:00
US FDA approved Lynparza for pancreatic cancerMon 30/12/19 | 07:00
Enhertu (trastuzumab deruxtecan) approved in USMon 23/12/19 | 07:00
Triple-combination approved in China for COPDMon 23/12/19 | 07:00
AstraZeneca divests rights to Arimidex and CasodexFri 20/12/19 | 07:00
FDA panel backs Lynparza use for pancreatic cancerTue 17/12/19 | 18:06
Seroquel rights agreement complete: Europe, RussiaMon 16/12/19 | 07:00
Imfinzi approved in China for Stage III NSCLCThu 12/12/19 | 07:00
Trastuzumab deruxtecan achieves ORR of 60.9%Wed 11/12/19 | 13:00
Lynparza approved in China for 1L BRCAm ovarianThu 05/12/19 | 07:00
AstraZeneca divests Seroquel rights: US and CanadaTue 03/12/19 | 07:00
Block listing Interim ReviewMon 02/12/19 | 15:00
Total Voting RightsMon 02/12/19 | 15:00
Imfinzi granted FDA Priority Review for SCLCFri 29/11/19 | 07:00
Calquence approved in CLL in the USThu 21/11/19 | 18:15
Qtrilmet approved in the EU for treatment of T2DFri 15/11/19 | 07:00
FDA accepts regulatory submission for selumetinibThu 14/11/19 | 07:00
Anifrolumab demonstrated superiority in TULIP 2Tue 12/11/19 | 07:00
Roxadustat pooled analyses: no increased CV riskMon 11/11/19 | 07:00
Roxadustat significantly increased haemoglobinFri 08/11/19 | 07:00
Calquence data to show improved progression-freeWed 06/11/19 | 14:10
Total Voting RightsFri 01/11/19 | 15:00
AstraZeneca divests rights to Seroquel andWed 30/10/19 | 07:00
Imfinzi and Imfinzi plus tremelimumab delayedMon 28/10/19 | 15:31
AstraZeneca year-to-date and Q3 2019 resultsThu 24/10/19 | 07:00
Farxiga approved in the US to reduce the risk ofMon 21/10/19 | 07:00
Trastuzumab deruxtecan granted FDA Priority ReviewThu 17/10/19 | 07:00
Holding(s) in CompanyFri 04/10/19 | 15:04
Holding(s) in CompanyFri 04/10/19 | 15:00
Fasenra approved in the US for self-administrationFri 04/10/19 | 07:00
Director DeclarationThu 03/10/19 | 16:00
Total Voting RightsTue 01/10/19 | 15:00
AstraZeneca divests rights for Losec to CheplapharTue 01/10/19 | 07:05
Update on US regulatory review of PT010 in COPDTue 01/10/19 | 07:00
Lynparza more than doubled the time withoutMon 30/09/19 | 15:30
Lynparza improved the time women lived withoutMon 30/09/19 | 07:00
Tagrisso is the only 1st-line treatment for EGFR-Mon 30/09/19 | 07:00
Qtrilmet recommended for approval in EU by CHMPMon 23/09/19 | 07:00
AstraZeneca amends collaboration with IronwoodWed 18/09/19 | 07:00
Imfinzi is first immunotherapy to show bothMon 09/09/19 | 08:38
Tagrisso approved in China as a 1st-line treatmentWed 04/09/19 | 07:11
Total Voting RightsMon 02/09/19 | 15:00
Brilinta reduced the risk of cardiovascular eventsMon 02/09/19 | 07:05
Detailed results from Phase III DAPA-HF trialMon 02/09/19 | 07:00
Anifrolumab Phase III trial meets primary endpointThu 29/08/19 | 07:00
Fasenra granted US Orphan Drug Designation forWed 28/08/19 | 07:05
Breztri Aerosphere Phase III ETHOS trial metWed 28/08/19 | 07:00
AstraZeneca agrees to buy US FDA Priority ReviewThu 22/08/19 | 07:00
Roxadustat approved in China for the treatment ofThu 22/08/19 | 07:00
Update on the Phase III NEPTUNE trialWed 21/08/19 | 07:00
Farxiga met primary endpoint in landmark Phase IIITue 20/08/19 | 07:00
Directorate ChangeMon 19/08/19 | 07:00
Lynparza Phase III PAOLA-1 trial met primary endpoWed 14/08/19 | 07:00
Calquence granted US Breakthrough Therapy DesignatWed 14/08/19 | 07:00
Amendment: Tagrisso significantly improves overallFri 09/08/19 | 09:28
Lynparza Phase III PROfound trial in HRR*Wed 07/08/19 | 07:00
Forxiga label updated in the EU in type-2 diabetesMon 05/08/19 | 07:00
Total Voting RightsThu 01/08/19 | 15:00
AZN: H1 2019 ResultsThu 25/07/19 | 07:00
Update on US regulatory decision for FarxigaMon 15/07/19 | 07:00
Imfinzi granted US Orphan Drug Designation forFri 12/07/19 | 07:00
Total Voting RightsMon 01/07/19 | 15:00
Fasenra receives positive EU CHMP opinion for selfMon 01/07/19 | 07:00
Forxiga receives positive EU CHMP opinion forMon 01/07/19 | 07:00
Imfinzi improves overall survival at interimThu 27/06/19 | 07:00
Breztri Aerosphere (PT010) approved in Japan forWed 19/06/19 | 07:00
Bevespi Aerosphere approved by the JapaneseWed 19/06/19 | 07:00
Lynparza approved in Japan for 1st-lineWed 19/06/19 | 07:00
Lynparza approved in the EU for 1st-lineTue 18/06/19 | 07:00
Calquence significantly prolonged the time patientMon 17/06/19 | 07:00
Publication of a ProspectusWed 12/06/19 | 16:45
Calquence Phase III ELEVATE-TN trial met primaryThu 06/06/19 | 07:00
Total Voting RightsMon 03/06/19 | 15:00
Block listing Interim ReviewMon 03/06/19 | 15:00
Lynparza nearly doubled time patients lived withMon 03/06/19 | 07:00
Pooled analyses of the roxadustat global Phase IIIFri 10/05/19 | 07:00
Director/PDMR ShareholdingWed 08/05/19 | 14:00
Director DeclarationWed 08/05/19 | 11:00
Trastuzumab deruxtecan demonstrated clinicallyWed 08/05/19 | 07:00
Calquence PhIII ASCEND trial met primary endpointTue 07/05/19 | 07:00
Qternmet XR approved in the US for type-2 diabetesFri 03/05/19 | 07:00
Total Voting RightsWed 01/05/19 | 15:00
Director/PDMR ShareholdingWed 01/05/19 | 12:00
Lynparza receives positive EU CHMP opinion for 1stMon 29/04/19 | 07:00
Result of AGMFri 26/04/19 | 17:45
AZN: Q1 2019 ResultsFri 26/04/19 | 07:00
Lynparza approved in EU for the treatment of germlWed 10/04/19 | 07:00
Holding(s) in CompanyThu 04/04/19 | 13:30
Director/PDMR ShareholdingWed 03/04/19 | 10:00
Total Voting RightsTue 02/04/19 | 15:00
AstrazenecaMon 01/04/19 | 18:00
Total Voting RightsMon 01/04/19 | 15:00
Selumetinib gets Breakthrough Therapy DesignationMon 01/04/19 | 07:00
Results of PlacingFri 29/03/19 | 17:15
AZ and Daiichi Sankyo enter collaboration in novelFri 29/03/19 | 07:00
Proposed placing of new ordinary sharesFri 29/03/19 | 07:00
Forxiga approved in Japan for type-1 diabetesWed 27/03/19 | 07:00
Forxiga approved in Europe for type-1 diabetesMon 25/03/19 | 07:00
US FDA grants saracatinib ODD for IPFMon 18/03/19 | 07:00
Notice of AGMThu 14/03/19 | 12:00
Director/PDMR ShareholdingTue 12/03/19 | 12:00
Filing of Form 20-F with SECWed 06/03/19 | 07:00
Annual Financial ReportTue 05/03/19 | 11:00
Holding(s) in CompanyMon 04/03/19 | 16:04
Total Voting RightsFri 01/03/19 | 15:00
Lynparza receives positive EU CHMP opinionFri 01/03/19 | 13:45
Lynparza significantly delayed disease progressionTue 26/02/19 | 07:00
Brilinta's PhIII THEMIS trial met primary endpointMon 25/02/19 | 07:00
AstraZeneca Full-Year and Q4 2018 ResultsThu 14/02/19 | 07:00
US FDA grants Fasenra Orphan Drug DesignationWed 06/02/19 | 07:00
US FDA grants Breakthrough Therapy DesignationTue 05/02/19 | 07:05
EMA grants PRIME eligibility for MEDI8897Tue 05/02/19 | 07:00
Total Voting RightsFri 01/02/19 | 15:00
Forxiga receives positive EU CHMP opinionFri 01/02/19 | 13:17
Completion of divestment of US Synagis rightsFri 25/01/19 | 14:00
AstraZeneca announces organisational changesMon 07/01/19 | 13:00
Total Voting RightsWed 02/01/19 | 15:00
Bevespi Aerosphere approved in the EU for COPDThu 20/12/18 | 13:47
Lynparza meets primary endpoint in SOLO-3 trialThu 20/12/18 | 07:05
Phase III ROCKIES and OLYMPUS roxadustat trialsThu 20/12/18 | 07:00
FDA approves Lynparza as 1L maintenance therapyWed 19/12/18 | 18:31
Roxadustat approved in China for the treatment ofTue 18/12/18 | 09:09
Directorate ChangeFri 14/12/18 | 07:00
Update on the Phase III EAGLE trial of ImfinziFri 07/12/18 | 07:00
Divestment of rights to Covis completedThu 06/12/18 | 07:00
Director/PDMR ShareholdingTue 04/12/18 | 15:00
Total Voting RightsMon 03/12/18 | 16:00
Block listing Interim ReviewMon 03/12/18 | 16:00
Grünenthal Agreement for Nexium, Vimovo CompletedMon 03/12/18 | 07:00
US FDA grants Fasenra ODD for EGPAMon 26/11/18 | 07:00
AstraZeneca provides update on Phase III MYSTICFri 16/11/18 | 07:00
AstraZeneca to divest US Synagis rights to SobiTue 13/11/18 | 07:00
US FDA accepts regulatory submission for LynparzaMon 12/11/18 | 07:05
Farxiga significantly reduced hospitalisation forMon 12/11/18 | 07:00
AZN: Year-to-Date and Q3 2018 ResultsThu 08/11/18 | 07:00
Divestment of rights to Covis PharmaTue 06/11/18 | 07:00
Total Voting RightsThu 01/11/18 | 15:00
Additional financial information-Grünenthal dealWed 31/10/18 | 09:45
Grünenthal Agreement for rights to Nexium, VimovoTue 30/10/18 | 07:00
AstraZeneca Extends Innate Pharma CollaborationTue 23/10/18 | 07:00
Lynparza shows 70% reduction in PFS ovarian cancerMon 22/10/18 | 07:00
CHMP positive opinion Bevespi AerosphereFri 19/10/18 | 13:09
FDA Orphan Drug for Lynparza in pancreatic cancerTue 16/10/18 | 07:00
Total Voting RightsMon 01/10/18 | 15:00
Atacand Agreement with Cheplapharm CompletedMon 01/10/18 | 07:00
Previous Announcement Regarding Appointment Of NEDFri 28/09/18 | 16:00
Overall survival data for Imfinzi: Stage III NSCLCTue 25/09/18 | 13:15
EMA approves AZ's Imfinzi for Stage III NSCLCMon 24/09/18 | 16:10
Farxiga gets positive result in DECLARE-TIMI 58Mon 24/09/18 | 07:00
FDA approves AZ's Lumoxiti in hairy cell leukaemiaFri 14/09/18 | 07:00
Tezepelumab FDA Breakthrough Therapy DesignationFri 07/09/18 | 07:00
Directorate ChangeThu 06/09/18 | 07:00
Total Voting RightsMon 03/09/18 | 15:00
AstraZeneca Update on Anifrolumab in SLEFri 31/08/18 | 07:00
EC approves Bydureon BCise device for T2 diabetesThu 30/08/18 | 07:00
AstraZeneca PIIIb trial update for Bevespi in COPDThu 23/08/18 | 07:00
AZ's Tagrisso approved in Japan for 1st-line NSCLCTue 21/08/18 | 07:00
AstraZeneca prices a $3bn bond issueWed 15/08/18 | 07:00
EMA grants OD for selumetinib in NF1Fri 03/08/18 | 07:00
Total Voting RightsWed 01/08/18 | 15:00
CHMP recommends Imfinzi for Stage III nsclcFri 27/07/18 | 14:00
AZN: H1 2018 ResultsThu 26/07/18 | 07:00
Atacand to be divested to Cheplapharm in EuropeTue 24/07/18 | 07:00
Holding(s) in CompanyWed 18/07/18 | 16:11
Holding(s) in CompanyWed 18/07/18 | 12:00
Total Voting RightsMon 02/07/18 | 15:00
Lynparza approved in Japan for BRCAm breast cancerMon 02/07/18 | 07:00
Imfinzi approved in Japan for Stage III nsclcMon 02/07/18 | 07:00
Bydureon receives positive CHMP opinion for BCiseFri 29/06/18 | 15:00
AZ and Luye Pharma complete agreement for SeroquelThu 28/06/18 | 13:30
Lynparza: significant PFS 1st-line ovarian cancerWed 27/06/18 | 07:00
Board Committee ChangesTue 26/06/18 | 07:00
Publication of a ProspectusFri 22/06/18 | 07:00
Update: lanabecestat Phase III Alzheimer's trialsTue 12/06/18 | 07:00
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLCFri 08/06/18 | 17:30
Director DeclarationFri 08/06/18 | 07:00
Block listing Interim ReviewFri 01/06/18 | 15:00
Total Voting RightsFri 01/06/18 | 15:00
Director DeclarationFri 01/06/18 | 11:00
Update on TERRANOVA PIII trial for Fasenra in COPDWed 30/05/18 | 07:00
AZ's Imfinzi: significant OS in Stage III nsclcFri 25/05/18 | 07:00
AZ regulatory submission in Japan for ForxigaMon 21/05/18 | 07:00
US FDA approves Lokelma for adult hyperkalaemiaMon 21/05/18 | 07:00
Result of AGMFri 18/05/18 | 17:30
AZN: Q1 2018 ResultsFri 18/05/18 | 07:00
AstraZeneca update on Fasenra PIII trial in COPDFri 11/05/18 | 07:00
EMA approves Lynparza: maintenance ovarian cancerTue 08/05/18 | 11:00
AZ and Luye Pharma enter agreement for SeroquelTue 08/05/18 | 07:00
Director DeclarationFri 04/05/18 | 12:00
Total Voting RightsTue 01/05/18 | 15:00
AZ: positive CHMP for Tagrisso first-line nsclcFri 27/04/18 | 12:30
AstraZeneca:high level results of the ARCTIC trialTue 24/04/18 | 07:00
FDA approves Tagrisso for 1st-line use in NSCLCThu 19/04/18 | 07:00
Notice of AGMFri 13/04/18 | 11:00
Directorate ChangeThu 05/04/18 | 07:00
Total Voting RightsTue 03/04/18 | 15:00
AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EUTue 03/04/18 | 07:00
FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIATue 03/04/18 | 07:00
Director/PDMR ShareholdingWed 28/03/18 | 15:00
Director/PDMR ShareholdingMon 26/03/18 | 15:00
Lokelma approved in the EUThu 22/03/18 | 16:48
ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINEMon 12/03/18 | 07:00
Filing of Form 20-F with SECWed 07/03/18 | 07:00
Annual Financial ReportTue 06/03/18 | 11:00
Total Voting RightsThu 01/03/18 | 15:00
Lynparza CHMP for ovarian cancer maintainanceFri 23/02/18 | 12:35
AstraZeneca's IMFINZI approved for Stage III nsclcMon 19/02/18 | 07:00
Selumetinib in NF1 gets FDA orphan drug statusThu 15/02/18 | 07:00
Director/PDMR ShareholdingMon 05/02/18 | 14:00
AZN: Full-Year 2017 ResultsFri 02/02/18 | 07:00
Total Voting RightsThu 01/02/18 | 15:00
AZ Reports Phase III Results for PT010 in COPDFri 26/01/18 | 18:20
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCERFri 19/01/18 | 07:00
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPANFri 19/01/18 | 07:00
FDA approves Lynparza for metastatic breast cancerFri 12/01/18 | 16:10
AstraZeneca's Fasenra approved in the EUWed 10/01/18 | 15:10
Total Voting RightsTue 02/01/18 | 15:00
Director/PDMR ShareholdingThu 28/12/17 | 14:00
FDA accepts Tagrisso submission for 1st-line nsclcMon 18/12/17 | 07:00
Director/PDMR ShareholdingFri 15/12/17 | 12:00
Total Voting RightsFri 01/12/17 | 15:00
Block listing Interim ReviewFri 01/12/17 | 15:00
EMA accepts Tagrisso submission for 1st-line nsclcTue 28/11/17 | 07:00
AZ submits Tagrisso in Japan for 1st-line nsclcMon 27/11/17 | 07:00
AZ Fasenra receives FDA approval for severe asthmaWed 15/11/17 | 07:00
BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMAFri 10/11/17 | 11:35
AZN: Year-To-Date and Q3 2017 Results AnnouncementThu 09/11/17 | 07:00
Total Voting RightsWed 01/11/17 | 15:00
ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEALWed 01/11/17 | 07:03
AstraZeneca tralokinumab update in severe asthmaWed 01/11/17 | 07:00
US FDA approves AstraZeneca's Calquence for MCLTue 31/10/17 | 17:05
AZ and MSD rapidly advance Lynparza in JapanMon 23/10/17 | 07:05
US FDA approves Bydureon BCise for type-2 diabetesMon 23/10/17 | 07:00
FDA Priority Review for Lynparza in breast cancerWed 18/10/17 | 07:00
FDA accepts sBLA file for Imfinzi; priority reviewTue 17/10/17 | 07:00
FDA grants Tagrisso BTD for 1st-line EGFR nsclcMon 09/10/17 | 07:00
Total Voting RightsMon 02/10/17 | 15:00
Director/PDMR ShareholdingTue 26/09/17 | 12:00
Aspen acquires remaining rights to AZ anaestheticsThu 14/09/17 | 07:00
IMFINZI superior PFS in Stage III lung cancerMon 11/09/17 | 07:00
Tagrisso potential standard of care in lung cancerMon 11/09/17 | 07:00
Celgene and AZ update on Fusion trial programmeThu 07/09/17 | 12:39
AZ tezepelumab cuts exacerbations in severe asthmaThu 07/09/17 | 07:00
AZ Duaklir improves lung function in COPD patientsThu 07/09/17 | 07:00
Directorate ChangeTue 05/09/17 | 07:00
Total Voting RightsFri 01/09/17 | 15:00
Faslodex gets US FDA OK for expanded use in breastTue 29/08/17 | 07:00
Lynparza gets broad FDA approval in ovarian cancerFri 18/08/17 | 07:00
Directorate ChangeWed 16/08/17 | 07:00
Holding(s) in CompanyMon 14/08/17 | 16:30
Publication of a ProspectusThu 10/08/17 | 13:30
AZ acalabrutinib submission accepted by US FDAWed 02/08/17 | 07:00
Total Voting RightsTue 01/08/17 | 15:00
BTD for AZ's acalabrutinib in mantle cell lymphomaTue 01/08/17 | 07:00
Imfinzi granted BTD by US FDA for Stage III nsclcMon 31/07/17 | 07:00
Director/PDMR ShareholdingFri 28/07/17 | 11:00
Tagrisso significantly improves FLAURAThu 27/07/17 | 07:15
AZ reports initial results from MYSTIC lung trialThu 27/07/17 | 07:11
AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEALThu 27/07/17 | 07:06
AstraZeneca PLC - H1 2017 ResultsThu 27/07/17 | 07:00
Faslodex receives EU approval for 1L breast cancerWed 26/07/17 | 16:46
Holding(s) in CompanyFri 21/07/17 | 15:45
Total Voting RightsMon 03/07/17 | 14:59
AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATIMon 03/07/17 | 07:00
AZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHALMon 03/07/17 | 07:00
Faslodex CHMP positive opinion in 1L breast cancerFri 23/06/17 | 12:46